Tuberculosis (TB) continues to be a major public health issue. Patients with Drug Resistance such as multidrug resistance (MDR) or extremely drug-resistant (XDR) TB show lower rates of treatment success as well, being 50% and 30% for each category, respectively. One of the main criteria for treating TB patients successfully is to administer the right treatment early. Whole-genome sequencing (WGS) is a technique that can be used to rapidly diagnose DR-TB by providing rapid, detailed and information for multiple gene regions across the whole TB genome. This approach overcomes many challenges associated with conventional phenotypic testing as well as the limitations of other less comprehensive molecular tests.
The use of WGS has been supported by global and national authorities for its advantages. It has been successfully implemented in other countries as a tool for mass patient use.
The TGS is based on such technology. It is a WGS based test powered by the ΩTB® analytics by HaystackAnalytics Pvt. Ltd. that combines genome sequencing and analysis for a faster, more sensitive, more reliable, and cost-effective method of tuberculosis diagnosis.